证券代码：838275 证券简称：驱动力 公告编号：2025-086 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 会议召开符合《公司法》等法律、法规及本公司章程的有关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 1.议案内容： 公司根据 2025 年半年度经营情况及财务状况，编制了《2025 年半年度报告》 及《2025 年半年度报告摘要》。 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 广东驱动力生物科技集团股份有限公司 本议案无需提交股东会审议。 （二）审议通过《关于公司<2025 年半年度募集资金存放、管理与实际使用情况 的专项报告>的议案》 1.议案内容： 报告期内，公司按照相关法律法规、《公司章程》及《募集资金管理制度》 的有关规定，对募集资金进行存放与使用管理，并编制了 2025 年半年度募集资 ...

证券代码：838275 证券简称：驱动力 公告编号：2025-085 广东驱动力生物科技集团股份有限公司 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 2.议案表决结果：同意 5 票；反对 0 票；弃权 0 票。 该议案已经公司审计委员会审议通过。 3.回避表决情况： 本议案不涉及关联事项，无需回避表决。 （一）会议召开情况 1.会议召开时间：2025 年 8 月 21 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出董事会会议通知的时间和方式：2025 年 8 月 11 日以书面方式发出 5.会议主持人：董事长刘平祥先生 6.会议列席人员：公司监事及高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》和《公司章程》的规定，决议合法有 效。 （二）会议出席情况 会议应出席董事 5 人，出席和授权出席董事 5 人。 二、议案审议情况 （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议 ...

Market Overview - The animal health sector experienced a decline of 0.76% on August 22, with Yongshun Biological leading the drop [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Individual Stock Performance - Yongshun Biological (code: 839729) closed at 11.18, down 4.36% with a trading volume of 91,600 shares and a turnover of 102 million yuan [1] - Dayu Biological (code: 871970) closed at 10.13, down 2.78% with a trading volume of 32,700 shares and a turnover of 33.49 million yuan [1] - Shunlian Biological (code: 688098) closed at 12.74, down 2.00% with a trading volume of 317,600 shares and a turnover of 412 million yuan [1] - Other notable declines include Xianfeng Holdings (code: 002141) down 1.79% and Jinhai Biological (code: 002688) down 1.36% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 74.19 million yuan from institutional investors, while retail investors had a net inflow of 91.60 million yuan [1] - Key stocks with significant capital flow include: - Huisheng Biological (code: 300871) with a net outflow of 9.62 million yuan from institutional investors [2] - Kexin Biological (code: 688526) with a net inflow of 7.28 million yuan from institutional investors [2] - ST Lvkang (code: 002868) had a net outflow of 3.99 million yuan from institutional investors but a net inflow of 3.77 million yuan from retail investors [2]

Core Viewpoint - The company reported a significant increase in total revenue and net profit for the six months ending June 30, 2025, driven by diversified business operations and a strong performance in overseas markets [1][3]. Financial Summary - Total revenue reached RMB 769.15 million, a year-on-year increase of 16.8% [3]. - Gross profit was RMB 230.87 million, reflecting a growth of 10.3% compared to the previous year [3]. - Profit before tax was RMB 27.92 million, up by 3.2% year-on-year [3]. - Net profit amounted to RMB 22.57 million, representing a 15.9% increase from the prior period [3]. Overseas Market Growth - The overseas market experienced explosive growth, with export revenue reaching RMB 38 million, expanding into 14 emerging markets including Southeast Asia, the Middle East, Central Asia, Africa, and South America [4]. - The establishment of a wholly-owned subsidiary in Tashkent, Uzbekistan, marked a significant step in the company's global expansion, achieving rapid customer engagement and vehicle procurement [5]. - The upgrade of the subsidiary in Horgos strengthened the supply chain support for the Central Asian market, laying a solid foundation for future growth [6]. External Market Dynamics - The external environment has accelerated the growth of overseas business, with China's new energy vehicle exports surging by 71.3% in the first half of 2025 [7]. - Policy support, including the online streamlining of export licenses and the removal of loan limits for new energy vehicles, has provided a robust foundation for the company's international strategy [7]. - The demand for ride-hailing compliance in Central Asia and the rapid adoption of new energy vehicles in the Middle East and Southeast Asia have created significant growth opportunities [7]. Domestic Business Performance - Despite the focus on international markets, the company maintained steady growth domestically, expanding its self-operated sales network from 89 to 110 locations [8]. - Strategic cooperation with Tuhu Car Maintenance has deepened, with service points exceeding 7,000 across major cities, enhancing customer experience [8]. Digital Transformation and New Business Initiatives - The company is accelerating its digital transformation, increasing the number of digital employees to 139 and achieving a 60% automation rate in credit approval processes [9]. - The launch of a smart tax platform has enabled full-process automation for financial and tax operations, supporting cross-border compliance [9]. - A subsidiary focused on low-altitude economy has received operational certification, with plans to implement applications in logistics and inspections [9]. Future Outlook - The chairman emphasized the commitment to accelerating overseas market expansion, particularly in Central Asia, while enhancing domestic channels and digital applications [10]. - The internationalization strategy is viewed as a core driver of future performance [10].

证券之星消息，8月20日动物保健板块较上一交易日上涨0.27%，贤丰控股领涨。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002141 | 后丰控股 | 4.66 | 9.91% | 128.85万 | | 5.73亿 | | 688526 | 科前生物 | 17.75 | 1.02% | 3.69万 | | 6491.03万 | | 838275 | 驱动力 | 10.24 | 0.69% | 2.68万 | | 2725.11万 | | 603566 | 普莱柯 | 15.30 | 0.39% | 5.28万 | | 8055.89万 | | 600195 | 中牧股份 | 7.70 | 0.39% | 10.24万 | | 7851.28万 | | 871970 | 大禹生物 | 10.27 | 0.39% | 3.79万 | | 3888. ...

"为中国跑者创造属于他们的跑鞋，为他们突破成绩保驾护航，是品牌的核心战略。"发布会后，特步集 团董事局主席兼CEO、中国田径协会特邀副主席丁水波告诉《记者去哪儿》栏目，一双好的跑鞋，要经 过无数的测验和调整，这背后，需要领先技术作为支撑。 记者了解到，截至2025年，品牌科研投入已累计超过20亿元，获得专利超1900件，为产品迭代升级提供 坚实的技术支撑。据介绍，品牌打造XTEP POWER科技矩阵，将天问二号小行星探测器太阳翼材料PI 纤维和嫦娥6号在月球背面动态展示旗帜材料玄武岩纤维应用在跑鞋不同类型的碳板里，助力跑者速度 更进一步。 依托超大规模市场优势，我国首发经济蓬勃发展。新产品、新业态、新模式、新服务、新技术以及开设 首店等经济活动正以创新丰富供给，以供给激活发展动能。人民网《记者去哪儿》栏目推出"首发时 刻"系列报道，进一步聚焦首发经济影响力、辐射力。 当广泛应用在卫星、火箭、深空探测器、飞机等航空航天部件上的PI纤维应用在跑鞋里，会带给跑者哪 些新体验？近日，特步新一代冠军版跑鞋发布会在厦门举行，160X 7代全新阵容亮相，从产品性能的升 级，到科技实力的进阶，科技之力正助力探索运动极限。 " ...

Core Insights - The company achieved a revenue of 183 million yuan, representing a year-on-year growth of 19.76%, and a net profit of 53.66 million yuan, with a year-on-year increase of 40.91% in the first half of 2025 [1][2] Business Performance - The two core business segments, industrial purification and analytical chromatography, showed differentiated growth, with industrial purification becoming the main driver of revenue growth, generating 120 million yuan in sales, a year-on-year increase of 28.59%, accounting for 65.97% of total revenue [2] - The customer structure improved, with a significant increase in the number of major clients, and over 60% of the revenue from products used in pharmaceutical companies' production or phase III clinical trials [2][3] Technological and Competitive Advantages - The company possesses core technologies in microsphere preparation, surface modification, and functional group-based materials, allowing it to provide comprehensive technical services and maintain a competitive edge over foreign counterparts [3][4] - The company's products have been registered with the FDA DMF, meeting high domestic demand and supporting international expansion [4] R&D and Capacity Expansion - In the first half of 2025, the company invested 23.90 million yuan in R&D, with an R&D expense ratio of 13.09%, enhancing its product line and launching several new industrial purification products [5] - The production capacity at the Yangzhou facility, which began operations in 2021, reached 24,800 liters per year, with a 100% delivery rate and 113 clients audited [5][6] Market Outlook - The global market for analytical chromatography is expected to grow, with an estimated production of 4.5 million chromatography columns and a market size of 3.03 billion USD by 2025 [7] - The company plans to focus on analytical chromatography and industrial purification, increasing R&D investment and expanding global presence to sustain growth and maintain industry leadership [7]

Core Viewpoint - The semiconductor sector is currently in an upward cycle, driven by the strong performance of artificial intelligence (AI) and a recovery in the industrial sector, which is expected to benefit Chinese semiconductor manufacturers significantly in the future [1][2]. Group 1: Market Performance - As of August 19, 2025, the Shanghai Stock Exchange's Sci-Tech Innovation Board Semiconductor Materials and Equipment Theme Index fell by 1.01%, with mixed performance among constituent stocks [1]. - Leading stocks included Jing Sheng Co., which rose by 6.09%, and Shen Gong Co., which increased by 3.87%, while Shanghai Hejing fell by 5.64% [1]. - The Sci-Tech Semiconductor ETF (588170) decreased by 1.33%, with a latest price of 1.11 yuan, indicating a potential opportunity for investment during the pullback [1]. Group 2: Investment Logic - The investment logic in the semiconductor sector can be divided into two main lines: focusing on cloud computing with self-sufficiency and looking at downstream growth in terminal markets [1]. - The semiconductor equipment and materials industry is crucial for domestic substitution, characterized by low domestic replacement rates and high ceilings for domestic alternatives [2]. - The sector is expected to benefit from the expansion of semiconductor demand driven by the AI revolution, technology restructuring, mergers and acquisitions, and advancements in lithography technology [2].

Group 1 - The current market rally is driven by a reassessment of confidence in the Chinese economy, which has shown resilience despite external pressures such as tariffs [1][2] - Significant events in various sectors, including AI, pharmaceuticals, and military, have bolstered market confidence in Chinese assets [1] - The market is experiencing a "slow bull" trend, differing from previous years, with a more gradual increase in stock prices and less reliance on high-risk funding [3] Group 2 - The overall profit growth has not fully materialized, indicating that the current market sentiment is more about restoring confidence rather than immediate financial performance [3] - Institutional investors are gradually reallocating funds from the bond market to the stock market, reflecting a rational assessment of valuations [3] - The market has not seen a significant influx of retail investors, with new account openings and fund subscriptions remaining stable [3]

证券之星消息，8月18日动物保健板块较上一交易日上涨2.2%，申联生物领涨。当日上证指数报收于 3728.03，上涨0.85%。深证成指报收于11835.57，上涨1.73%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688098 | 申联生物 | 12.83 | 20.02% | 13.27万 | 1.69 Z | | 300871 | 回盛生物 | 24.26 | 7.87% | 30.00万 | 7.20亿 | | 838275 | 驱动力 | 10.02 | 6.60% | 4.35万 | 4273.62万 | | 002141 | 贤丰控股 | 3.91 | 4.27% | 1 85.59万 | 3.38亿 | | 839729 | 永顺生物 | 9.95 | 3.65% | 3.11万 | 3066.40万 | | 871970 | 大禹生物 | 9.98 | 3.42% | 2.96万 | 2928.24万 | | 300119 | 瑞普生物 | ...